Related Experiment Video
Updated: Apr 20, 2026
Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
Published on: August 1, 2025
Targeting the alternatively spliced soluble isoform of CTLA-4: prospects for immunotherapy?
Frank J Ward1, Lekh N Dahal, Rahul C Khanolkar
1Section of Immunology & Infection, Division of Applied Medicine, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, UK.
Abstract:
CTLA-4 is an inhibitory protein that contributes to immune homeostasis and tolerance, a role that has led to its exploitation as a therapeutic in several clinical settings including cancer and autoimmune disease. Development of CTLA-4 therapies focused largely on the full-length receptor isoform but other CTLA-4 isoforms are also expressed, including a secretable form of CTLA-4 (soluble CTLA-4 [sCTLA-4]). The contribution of sCTLA-4 to immune regulation has been less well studied, primarily because it was identified some years after the original description of CTLA-4. Here, we examine how sCTLA-4 might contribute to immune regulation and ask whether it might be a biomarker to inform current CTLA-4 therapies or represent a novel CTLA-4 target for future therapeutics.
Insights
Soluble CTLA-4 (sCTLA-4) may impact immune regulation and inform CTLA-4 therapies. Further research is needed to determine if sCTLA-4 can serve as a biomarker or a novel therapeutic target.
Area of Science:
- Immunology
- Molecular Biology
- Therapeutics
Background:
- Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is crucial for immune homeostasis and tolerance.
- CTLA-4 therapies are established for cancer and autoimmune diseases, primarily targeting the full-length receptor.
- Other CTLA-4 isoforms, like soluble CTLA-4 (sCTLA-4), are expressed but less understood.
Purpose of the Study:
- To investigate the role of sCTLA-4 in immune regulation.
- To explore sCTLA-4's potential as a biomarker for existing CTLA-4 therapies.
- To assess sCTLA-4 as a novel therapeutic target.
Main Methods:
- Literature review and analysis of existing data on CTLA-4 isoforms.
- Exploration of immunological pathways involving sCTLA-4.
- Comparative analysis of full-length CTLA-4 and sCTLA-4 functions.
Main Results:
- sCTLA-4's contribution to immune regulation remains understudied.
- Identification of sCTLA-4 as a potential factor influencing immune responses.
- Potential for sCTLA-4 to modulate the efficacy of current CTLA-4 therapies.
Conclusions:
- sCTLA-4 warrants further investigation for its role in immune function.
- sCTLA-4 may serve as a valuable biomarker for CTLA-4-based treatments.
- sCTLA-4 represents a potential new avenue for therapeutic development in immune-related diseases.
